Last update 09 Jun 2025

LaNova Medicines (Zhejiang) Co., Ltd.

Private Company | Subsidiary Company|2021|Zhejiang Sheng, China|
www.lanovamedicines.com

Overview

Tags

Neoplasms
Digestive System Disorders
Endocrinology and Metabolic Disease
Antibody drug conjugate (ADC)

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Antibody drug conjugate (ADC)1
Top 5 TargetCount
CLDN18.2 x Tubulin1

Related

1
Drugs associated with LaNova Medicines (Zhejiang) Co., Ltd.
LM-302
Target
CLDN18.2 x Tubulin
Mechanism
CLDN18.2 inhibitors [+1]
Active Org.
LaNova Australia Pty Limited [+2]
Originator Org.
LaNova Medicines Ltd.LaNova Medicines Ltd.
Active Indication
CLDN18.2 positive Gastroesophageal junction adenocarcinoma [+11]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with LaNova Medicines (Zhejiang) Co., Ltd.
NCT06351020
/ RecruitingPhase 3
A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician's Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.
NCT05934331
/ RecruitingPhase 2
A Phase II, Open-Label, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of LM-302 Combined With Toripalimab in CLDN18.2 Positive Patients Advanced Gastro-Intestinal Cancer
CTR20231421
/ RecruitingPhase 2
一项评价 LM-302 联合特瑞普利单抗在 CLDN18.2 阳性的晚期消化道肿瘤受试者中的有效性、 安全性和耐受性的开放、多中心的Ⅱ期临床研究
[Translation] An open-label, multicenter phase II clinical study to evaluate the efficacy, safety, and tolerability of LM-302 combined with toripalimab in subjects with CLDN18.2-positive advanced gastrointestinal tumors
100 Clinical Results associated with LaNova Medicines (Zhejiang) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with LaNova Medicines (Zhejiang) Co., Ltd.
Login to view more data
100 Deals associated with LaNova Medicines (Zhejiang) Co., Ltd.
Login to view more data
100 Translational Medicine associated with LaNova Medicines (Zhejiang) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
LM-302
 ( CLDN18.2 x Tubulin )		Pancreatic Cancer
More
Phase 3
LM-102
 ( CLDN18.2 )		Advanced Malignant Solid Neoplasm
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free